LIQ861

Liquidia Receives Complete Response Letter from FDA for LIQ861 (treprostinil) Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension RESEARCH TRIANGLE PARK, N.C., Nov. 25, 2020 (GLOBE NEWSWIRE) — Liquidia Technologies, Inc., a wholly owned subsidiary of Liquidia Corporation (NASDAQ: